-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 FE/yVEO3t9tbXgKGLRWjN7yXIouH49Gtgt6U27jiCqC4IOQExExdOTR0D943K98r
 yTdd1v5r2V1Ai3s16ChwTw==

<SEC-DOCUMENT>0000910662-07-000296.txt : 20070618
<SEC-HEADER>0000910662-07-000296.hdr.sgml : 20070618
<ACCEPTANCE-DATETIME>20070618172205
ACCESSION NUMBER:		0000910662-07-000296
CONFORMED SUBMISSION TYPE:	20-F/A
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20061231
FILED AS OF DATE:		20070618
DATE AS OF CHANGE:		20070618

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TRINITY BIOTECH PLC
		CENTRAL INDEX KEY:			0000888721
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L2
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		20-F/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22320
		FILM NUMBER:		07926585

	BUSINESS ADDRESS:	
		STREET 1:		IDA BUSINESS PARK, BRAY, CO WICKLOW
		STREET 2:		IRELAND
		CITY:			DUBLIN IRELAND
		STATE:			L2
		ZIP:			18
		BUSINESS PHONE:		01135312955111

	MAIL ADDRESS:	
		STREET 1:		3 ROCK ROAD
		STREET 2:		SANDYFORD INDUSTRIAL ESTATES
		CITY:			DUBLIN IRELAND
		STATE:			L2
		ZIP:			18
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F/A
<SEQUENCE>1
<FILENAME>form20fa1.txt
<DESCRIPTION>AMENDMENT NO 1 FY 2006
<TEXT>


                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                   FORM 20-F/A
                                (Amendment No. 1)

                                   (MARK ONE)

       [ ] REGISTRATION STATEMENT PURSUANT TO SECTION 12(B) OR (G) OF THE
           SECURITIES EXCHANGE ACT OF 1934

                                       OR

       [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES
           EXCHANGE ACT OF 1934

       [X] For the fiscal year ended: December 31, 2006

                                       OR

       [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES
           EXCHANGE ACT OF 1934

                  For the transition period from _______ to __

                                       OR

       [ ] SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE
           SECURITIES EXCHANGE ACT OF 1934

       Date of event requiring this shell company report .................


                         Commission file number: 0-22320

                               Trinity Biotech plc
             ------------------------------------------------------
             (Exact name of Registrant as specified in its charter)

                                     Ireland
                 -----------------------------------------------
                 (Jurisdiction of incorporation or organization)

                  IDA Business Park, Bray, Co. Wicklow, Ireland
                  ---------------------------------------------
                    (Address of principal executive offices)

Securities registered or to be registered pursuant to Section 12(b) of the Act:

                                                    Name of each exchange
               Title of each class                   on which registered

           American Depository Shares               NASDAQ Stock Market LLC
   (each representing 4 'A' Ordinary Shares,
             par value US$0.0109)

<PAGE>


 Securities registered or to be registered pursuant to Section 12(g) of the Act:

                                      None
                                ----------------
                                (Title of Class)

              Securities for which there is a reporting obligation
                     pursuant to Section 15(d) of the Act:

                                      None
                              ---------------------
                              (Title of each class)

     Indicate the number of outstanding shares of each of the issuer's classes
of capital or common stock as of the close of the period covered by the annual
report: 73,601,497 Class 'A' Ordinary Shares and 700,000 Class 'B' Ordinary
Shares.

       Indicate by check mark if the registrant is a well-known seasoned issuer,
as defined in Rule 405 of the Securities Act.

                                   Yes __ No X

       If this report is an annual or transition report, indicate by check mark
if the registrant is not required to file reports pursuant to Section 13 or
15(d) of the Securities Exchange Act of 1934.

                                   Yes __ No X

     Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.

                                   Yes X No __

     Indicate by check mark whether the registrant is a large accelerated filer,
an accelerated filer or a non-accelerated filer. See definition of "accelerated
filer and large accelerated filer" in Rule 12b-2 of the Exchange Act:

  Large accelerated filer [ ] Accelerated filer [X] Non-accelerated filer [ ]

     Indicate by check mark which financial statement item the registrant has
elected to follow:
                              Item 17 __ Item 18 X


     If this is an annual report, indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Exchange Act).
     Yes __    No X

   This Report on Form 20-F/A is incorporated by reference into our Registration
Statement on Form F-3 File No. 333-112568, 333-116537, 333-103033, 333-107363,
333-114099 and 333-124385 and our Registration Statements on Form S-8 File No.
33-76384, 333-220, 333-5532, 333-7762 and 333-124384.


<PAGE>


                                EXPLANATORY NOTE

         Trinity Biotech plc (the "Company") is filing this Amendment No. 1 (the
"Amendment") to its Annual Report on Form 20-F for the fiscal year ended
December 31, 2006 (the "Original Filing"), which was filed with the U.S.
Securities and Exchange Commission on May 8, 2007.

         This Amendment is being filed to amend the exhibits listed in Item 19
to include a letter of consent from KMPG, which was inadvertently omitted from
the Original Filing.

         In addition, this Amendment corrects the cover page to the Original
Filing to revise the cover page items "Securities Registered Pursuant to Section
12(b) of the Act" and "Securities Registered Pursuant to Section 12(g) of the
Act." As a result of NASDAQ's transition to a national securities exchange on
August 1, 2006, the securities of NASDAQ-listed companies have now become
registered under Section 12(b) of the Securities Exchange Act of 1934, and the
name of the exchange upon which these securities are listed has been changed to
"The NASDAQ Stock Market LLC."

         Except as described above, no other changes have been made to the
Original Filing, and this Form 20-F/A does not amend, update or change the
financial statements or any other items or disclosures in the Original Filing.
This Form 20-F/A does not reflect events occurring after the filing of the
Original Filing or modify or update those disclosures, including any exhibits to
the Original Filing affected by subsequent events. Information not affected by
the changes described above is unchanged and reflects the disclosures made at
the time of the filing of the Original Filing on May 8, 2007.

ITEM 19.          EXHIBITS


     Exhibit No.    Description of Exhibit
     -----------    ----------------------

     12.1           Certification by Chief Executive Officer Pursuant to Section
                    302 of the Sarbanes- Oxley Act of 2002.

     12.2           Certification by Chief Financial Officer Pursuant to Section
                    302 of the Sarbanes- Oxley Act of 2002.

     13.1           Certification  by Chief  Executive  Officer  Pursuant  to 18
                    U.S.C.  Section 1350, As Adopted  Pursuant to Section 906 of
                    the Sarbanes-Oxley Act of 2002.(1)

     13.2           Certification  by Chief  Financial  Officer  Pursuant  to 18
                    U.S.C.  Section 1350, As Adopted  Pursuant to Section 906 of
                    the Sarbanes-Oxley Act of 2002.(2)

     15.1           Consent of KPMG.

         -------------------

          (1)  Previously  filed with the Company's Form 20-F for the year ended
          December 31, 2006.

          (2)  Previously  filed with the Company's Form 20-F for the year ended
          December 31, 2006.


<PAGE>


                                   SIGNATURES

The registrant hereby certifies that it meets all of the requirements for filing
on Form 20-F/A and that it has duly caused and authorized the undersigned to
sign this Amendment to the Annual Report on its behalf.


                                            TRINITY BIOTECH PLC



                                            By:  /s/ Ronan O'Caoimh
                                                 ------------------
                                                 Mr. Ronan O'Caoimh
                                                 Director/
                                                 Chief Executive Officer

                                            Date: June 18, 2007



                                            By: /s/ Rory Nealon
                                                ---------------
                                                Mr. Rory Nealon
                                                Director/
                                                Chief Financial Officer

                                            Date:  June 18, 2007


</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>2
<FILENAME>ex12_1.txt
<DESCRIPTION>SECTION 302(A) CERTIFICATION OF CEO
<TEXT>

                                                                    Exhibit 12.1

                            CERTIFICATION PURSUANT TO
                SECTION 302(a) OF THE SARBANES-OXLEY ACT OF 2002

I, Ronan O'Caoimh, certify that:

1. I have reviewed this annual report on Form 20-F, as amended by this Form
20-F/A of Trinity Biotech plc;

2. Based on my knowledge, this annual report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this annual
report;

3. Based on my knowledge, the financial statements, and other financial
information included in this annual report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this annual report;

4. The registrant's other certifying officers and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15(d)-15(e)) and internal control over
financial reporting (as defined in Exchange Act rules 13a-15(f) and 15d-15(f))
for the registrant and we have:

a) designed such disclosure controls and procedures, or caused such disclosure
controls and procedures to be designed under our supervision, to ensure that
material information relating to the registrant, including its consolidated
subsidiaries, is made known to us by others within those entities, particularly
during the period in which this annual report is being prepared;

b) designed such internal control over financial reporting, or caused such
internal control over financial reporting to be designed under our supervision,
to provide reasonable assurance regarding the reliability of financial reporting
and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles;

c) evaluated the effectiveness of the registrant's disclosure controls and
procedures and presented in this annual report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the
period covered by this annual report based on such evaluation; and

d) disclosed in this annual report any change in the registrant's internal
control over financial reporting that occurred during the period covered by this
annual report that has materially affected, or is reasonably likely to
materially affect, the registrant's internal control over financial reporting.

5. The registrant's other certifying officers and I have disclosed, based on our
most recent evaluation of internal control over financial reporting, to the
registrant's auditors and the Audit Committee of the registrant's Board of
Directors (or persons performing the equivalent function):

a) all significant deficiencies and material weaknesses in the design or
operation of internal controls over financial reporting which are reasonably
likely to adversely affect the registrant's ability to record, process,
summarise and report financial information; and

b) any fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant's internal control over
financial reporting.

Date: June 18, 2007
<PAGE>

/s/ Ronan O'Caoimh           *
- ----------------------------
Ronan O'Caoimh
Chief Executive Officer


* The originally executed copy of this Certification will be maintained at the
Company's offices and will be made available for inspection upon request.


</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.2
<SEQUENCE>3
<FILENAME>ex12_2.txt
<DESCRIPTION>SECTION 302(A) CERTIFICATION OF CFO
<TEXT>


                                                                    Exhibit 12.2

                            CERTIFICATION PURSUANT TO
                SECTION 302(a) OF THE SARBANES-OXLEY ACT OF 2002

I, Rory Nealon, certify that:

1. I have reviewed this annual report on Form 20-F, as amended by this Form
20-F/A, of Trinity Biotech plc;

2. Based on my knowledge, this annual report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this annual
report;

3. Based on my knowledge, the financial statements, and other financial
information included in this annual report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this annual report;

4. The registrant's other certifying officers and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15(d)-15(e)) and internal control over
financial reporting (as defined in Exchange Act rules 13a-15(f) and 15d-15(f))
for the registrant and we have:

a) designed such disclosure controls and procedures, or caused such disclosure
controls and procedures to be designed under our supervision, to ensure that
material information relating to the registrant, including its consolidated
subsidiaries, is made known to us by others within those entities, particularly
during the period in which this annual report is being prepared;

b) designed such internal control over financial reporting, or caused such
internal control over financial reporting to be designed under our supervision,
to provide reasonable assurance regarding the reliability of financial reporting
and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles;

c) evaluated the effectiveness of the registrant's disclosure controls and
procedures and presented in this report our conclusions about the effectiveness
of the disclosure controls and procedures, as of the end of the period covered
by this annual report based on such evaluation; and

d) disclosed in this annual report any change in the registrant's internal
control over financial reporting that occurred during the period covered by this
annual report that has materially affected, or is reasonably likely to
materially affect, the registrant's internal control over financial reporting.

5. The registrant's other certifying officers and I have disclosed, based on our
most recent evaluation of internal control over financial reporting to the
registrant's auditors and the Audit Committee of the registrant's Board of
Directors (or persons performing the equivalent function):

a) all significant deficiencies and material weaknesses in the design or
operation of internal control over financial reporting which are reasonably
likely to adversely affect the registrant's ability to record, process,
summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant's internal control over
financial reporting.

Date: June 18, 2007


<PAGE>

/s/ Rory Nealon            *
- ---------------------------
Rory Nealon
Chief Financial Officer


* The originally executed copy of this Certification will be maintained at the
Company's offices and will be made available for inspection upon request.


</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.1
<SEQUENCE>4
<FILENAME>ex15_1.txt
<DESCRIPTION>CONSENT OF KPMG
<TEXT>
            Consent of Independent Registered Public Accounting Firm



The Board of Directors
Trinity Biotech plc




We consent to the incorporation by reference in the registration statements on
Form F-3 (Nos. 333-103033, 333-107363, 333-114099 and 333-124385) and in the
registration statements on Form S-8 (Nos. 33-76384, 333-220, 333-5532, 333-7762
and 333-124384) of Trinity Biotech plc of our report dated May 8, 2007, with
respect to the consolidated balance sheets of Trinity Biotech plc as of December
31, 2006 and 2005, and the related consolidated statements of income, recognised
income and expense and cash flows for each of the years in the two-year period
ended December 31, 2006, and the accompanying financial statement schedule,
which report appears in the December 31, 2006, annual report on Form 20-F of
Trinity Biotech plc.






/s/ KPMG

KPMG
Dublin, Ireland


8 May 2007

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
